Non-CYP metabolism. Side effects such as nausea, vomiting and anorexia may be potentially porphyrinogenic through reduction in caloric intake.

Fluorinated nucleotide analogue administered as phosphate, slightly soluble in water.

Fludarabine is an antimetabolite antineoplastic agent used to treat chronic lymphatic leucemia of B-cell type in patients with sufficient bone marrow reserve. Administered orally or as an infusion. Common adverse reactions of fludarabine that can be confused with an acute porphyric attack are nausea, vomiting and peripheral neuropathy common. Side effects such as nausea, vomiting and anorexia may be potentially porphyrinogenic through reduction in caloric intake.

Fludarabine phosphate is rapidly dephosphorylated followed by selective distribution to leucemic cells, whereit is rephosphorylated to the active triphosphate nucleotide. This is eliminated from target cells with a half life of about 23 hours. The active metabolite F-ara-A formed on dephosphorylation of fludarabine is largely eliminatd by renal excretion (Ganhi et al, 2002). Not reported by Rendic (2002) as CYP-inductor or inhibitor.

No.